دورية أكاديمية
Impact of Direct‐Acting Antiviral Treatment for Hepatitis C on Cardiovascular Diseases and Extrahepatic Cancers
| العنوان: | Impact of Direct‐Acting Antiviral Treatment for Hepatitis C on Cardiovascular Diseases and Extrahepatic Cancers |
|---|---|
| المؤلفون: | Lam, Laurent, Fontaine, Hélène, Lapidus, Nathanael, Dorival, Céline, Bellet, Jonathan, Larrey, Dominique, Nahon, Pierre, Diallo, Alpha, Cagnot, Carole, Lusivika‐nzinga, Clovis, Téoulé, François, Hejblum, Gilles, Bourlière, Marc, Pol, Stanislas, Carrat, Fabrice |
| المساهمون: | Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Département d'hépatologie CHU Cochin, Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier), Génomique fonctionnelle des tumeurs solides = Functional Genomics of Solid Tumors CRC (FunGeST), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hôpital Avicenne AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), Hôpital Saint-Joseph Marseille, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Cité (UPCité), ANR-19-COHO-0002,Hepather (COHORTES),Therapeutic options for hepatitis B and/or C: a French nationwide cohort study(2019) |
| المصدر: | ISSN: 1053-8569. |
| بيانات النشر: | HAL CCSD Wiley |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Oral direct antiviral agents, Hepatitis C virus, Extrahepatic manifestations, Adverse events, SNDS, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.CAN]Life Sciences [q-bio]/Cancer |
| الوصف: | International audience ; Purpose: The impact of direct-acting antivirals (DAAs) on extrahepatic complications in chronic hepatitis C (CHC) patients remains poorly described. We estimated the association of DAAs with cardiovascular events and extrahepatic cancers.Methods: The prospective ANRS CO22 HEPATHER cohort was enriched with individual data until December 2018 from the French Health Insurance Database (SNDS). CHC patients were enrolled between August 2012 and December 2015 in 32 French hepatology centers. A total of 8148 CHC adults were selected. Cardiovascular events (stroke, acute coronary syndrome, pulmonary embolism, heart failure, arrhythmias and conduction disorders [ACD], peripheral arterial disease [PAD]) and extrahepatic solid cancers were derived from the SNDS. Associations between DAAs and extrahepatic events were estimated using marginal structural models, with adjustments for clinical confounders.Results: Analyses of 12 905 person-years of no DAA exposure and 22 326 person-years following DAA exposure showed a decreased risk of PAD after DAA exposure (hazard ratio [HR], 0.54; 95% CI, 0.33–0.89), a beneficial effect of DAAs on overall cardiovascular outcomes in patients with advanced fibrosis (aHR, 0.58; 95% CI, 0.42–0.79), and an increased risk of ACD (hazard ratio [HR], 1.46; 95% CI, 1.04–2.04), predominant after the first year following DAA initiation. There was no association between DAAs and extrahepatic cancer risk (HR, 1.23; 95% CI, 0.50–3.03).Conclusions: DAAs were not associated with extrahepatic cancer development or reduction. They were associated with a decreased risk of PAD and an increased risk of ACD, supporting long-term cardiac monitoring after DAA therapy. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36444965; hal-03883026; https://hal.science/hal-03883026Test; https://hal.science/hal-03883026/documentTest; https://hal.science/hal-03883026/file/Pharmacoepidemiology%20and%20Drug%20-%202022%20-%20Lam%20-%20Impact%20of%20Direct%25E2%2580%2590Acting%20Antiviral%20Treatment%20for%20Hepatitis%20C%20on%20Cardiovascular.pdfTest; PUBMED: 36444965 |
| DOI: | 10.1002/pds.5576 |
| الإتاحة: | https://doi.org/10.1002/pds.5576Test https://hal.science/hal-03883026Test https://hal.science/hal-03883026/documentTest https://hal.science/hal-03883026/file/Pharmacoepidemiology%20and%20Drug%20-%202022%20-%20Lam%20-%20Impact%20of%20Direct%25E2%2580%2590Acting%20Antiviral%20Treatment%20for%20Hepatitis%20C%20on%20Cardiovascular.pdfTest |
| حقوق: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.C84DDE62 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/pds.5576 |
|---|